Log in Start free

Vulnerability · Published Dec 2, 2025 · Assigned by icscert

CVE-2025-61940Mirion Medical EC2 Software NMIS BioDose Use of Client-Side Authentication

High 8.3

In plain English

A high-severity security flaw in EC2 Software NMIS BioDose from Mirion Medical. There are no confirmed reports of exploitation so far. The chance it is exploited in the next 30 days is estimated at 0.3% (higher than 28% of all known vulnerabilities).

Severity (CVSS 3.1)8.3High
Exploit odds (30 days)0.3%top 72.0% of all CVEs
Exploited in the wildNo reportsCISA SSVC: none
Attack toolingNoneno public tooling known

Official description

NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.

Affected products (as reported)

VendorProductVersions
Mirion Medical EC2 Software NMIS BioDose 0 – before 23.0

Weakness: CWE-603 · Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L

References